Back to results

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

Primary Purpose

Cancer of Unknown Primary Site

Status

Active

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

Alectinib

Vismodegib

Ipatasertib

Olaparib

Erlotinib

Bevacizumab

Vemurafenib

Cobimetinib

Trastuzumab Subcutaneous (SC)

Pertuzumab

Atezolizumab

Carboplatin

Paclitaxel

Cisplatin

Gemcitabine

Entrectinib

Ivosidenib

Pemigatinib

About this trial

This is an interventional treatment trial for Cancer of Unknown Primary Site

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histologically-confirmed unresectable cancer of unknown primary site (CUP) diagnosed according to criteria defined in the 2015 European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for CUP
No prior lines of systemic therapy for the treatment of CUP
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Candidate for platinum-based chemotherapy (according to the reference information for the intended chemotherapy)
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)
Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue sample </= 4 months old that is expected to be sufficient for generation of a comprehensive genomic profile at a central reference pathology laboratory

Exclusion Criteria:

Squamous cell CUP
Participants who can be assigned to a specific subset of CUP for which a specific treatment is recommended by the 2015 ESMO Clinical Practice Guidelines for CUP or with a clinical and IHC profile indicative of a specific primary tumor (favorable prognosis CUP subsets): Poorly differentiated carcinoma with midline distribution; women with papillary adenocarcinoma of the peritoneal cavity; women with adenocarcinoma involving only the axillary lymph nodes; squamous cell carcinoma of the cervical lymph nodes; poorly differentiated neuroendocrine tumors; men with blastic bone metastases and elevated prostate-specific antigen (PSA); participants with a single, small, potentially resectable tumor; colon cancer-type CUP, including participants with a CK7 negative, CK20 positive, CDX-2 positive immunohistochemistry profile; CK7-positive, CK20-negative and TTF-1 positive tumors in a context suggestive of lung adenocarcinoma or thyroid cancer; IHC profile definitely indicative of breast cancer OR an IHC profile indicative of breast cancer and either a history of breast cancer or lymph nodes in the drainage areas of the breast; high-grade serious carcinoma histology and elevated CA125 tumor marker and/or a mass in the gynecological tract or any tumor mass or lymph node in the abdominal cavity; IHC profile suggestive of renal cell carcinoma and renal lesions, with a Bosniak classification higher than IIF; IHC profile compatible with cholangiocarcinoma or pancreatobiliary (or upper gastrointestinal carcinoma) AND 1 or 2 liver lesions without extrahepatic disease or with only pulmonary metastases and/or lymph nodes in the drainage areas of the liver
Known presence of brain or spinal cord metastasis (including metastases that have been irradiated only)
Histology and immunohistology profiles (per 2015 ESMO guidelines) that are not adenocarcinoma or poorly differentiated carcinoma/adenocarcinoma
History or known presence of leptomeningeal disease
Known human immunodeficiency virus (HIV) infection
Significant cardiovascular disease
Prior allogeneic stem cell or solid organ transplantation
Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or for up to 7 months after the final dose of treatment

Sites / Locations

Blacktown Hospital
Northern Cancer Institute
Icon Cancer Foundation
Flinders Medical Centre
Peter MacCallum Cancer Center
LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Chemotherapie & Infektionskrankhei
Hospital Sao Rafael - HSR
Instituto Nacional de Cancer - INCa; Oncologia
Hospital Nossa Senhora da Conceicao
Hospital de Cancer de Barretos
Instituto do Cancer do Estado de Sao Paulo - ICESP
MHAT Nadezhda
MBAL Serdika EOOD
Bradford Hill Centro de Investigaciones Clinicas
James Lind Centro de Investigación Del Cáncer
Clinica del Country
Inst. Nacional de Cancerologia; Clinica de Seno
Oncomedica S.A.
Clinical Hospital Centre Zagreb
Masarykuv onkologicky ustav
Fakultni nemocnice Olomouc; Onkologicka klinika
Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
Aarhus Universitetshospital; Afdeling for Eksperimentel Klinisk Onkologi
Rigshospitalet; Onkologisk Klinik
North Estonia Medical Centre, Oncology and hematology Clinic; Department of Chemotherapy
Helsinki University Central Hospital; Dept of Oncology
Tampere University Hospital; Dept of Oncology
Ico - Paul Papin
CHRU Besançon
Institut Bergonie; Oncologie
CRLCC-Francois Baclesse; Oncologie Médicale
Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne
Centre Leon Berard
Institut Paoli-Calmettes; Oncologie Medicale 1
Institut régional du Cancer Montpellier
Centre Antoine Lacassagne
Institut Curie; Oncologie Medicale
CHU Lyon - Centre Hospitalier Lyon Sud
Centre Eugene Marquis; Service d'oncologie
CHU Strasbourg Hôpital Hautepierre
Hopital Foch; Oncologie
Institut Gustave Roussy
Universitätsklinikum Augsburg; II. Med. Klinik
Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
Onkologisches Zentrum - Onkologie Dachau
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
Universitätsklinikum Düsseldorf; Klinik für Hämatologie, Onkologie und Klinische Immunologie
Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie
Universitätsklinikum Frankfurt, UCT; Universitäres Centrum für Tumorerkrankungen
Universitätsklinikum Heidelberg;Innere Medizin V, Hämatologie/Onkologie
SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.
Universitätsklinikum Jena, Klinik für Innere Medizin II; Hämatologie und Internistische Onkologie
Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik
Klinikum Mannheim III. Medizinische Klinik
Klinikum der LMU München, Campus Großhadern, Krebszentrum München; Comprehensive Cancer Center LMU
Universitätsklinikum Münster, Medizinische Klinik A, Translationale Onkologie
RED-Oncology GmbH; Dres.Gerdt Hübner/Clemens Engels (Oldenburg)/Yael Bonnin-Gruber (Eutin)
Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine
IASO General Hospital of Athens
Univ General Hosp Heraklion; Medical Oncology
Uni Hospital of Ioannina; Oncology Dept.
Theagenio Anticancer Hospital; 3Rd Oncology Clinic
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
Budapesti Uzsoki Utcai Kórház; Onkoradiológiai Osztály
Bács-Kiskun Vármegyei Oktatókórház; Onkoradiológiai Központ
St Vincent'S Uni Hospital; Medical Oncology
Waterford Regional Hospital; Department Of Medical Oncology
Rabin MC; Davidof Center - Oncology Institute
Chaim Sheba medical center, Oncology division
Tel Aviv Sourasky Medical Ctr; Oncology
U. O. Oncologia Medica, Ospedale Santa Chiara
Policlinico Univ. - A.O. Mater Domini; U.O. Di Oncoematologia
Istituto Nazionale Tumori Fondazione G. Pascale
Arcispedale Santa Maria Nuova; Oncologia
Asst Papa Giovanni XXIII; Oncologia Medica
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
Aichi Cancer Center
National Cancer Center Hospital East
National Hospital Organization Kyushu Cancer Center
Seoul National University Hospital
Asan Medical Center
Samsung Medical Center
Severance Hospital, Yonsei University Health System; Oncology
Riga East Clinical University Hospital Latvian Oncology Centre
Health Pharma Professional Research
AVIX Investigación Clínica S.C
Erasmus MC
Universitair Medisch Centrum Utrecht
Ziekenhuis VieCuri Medisch Centrum
Sørlandet Sykehus Kristiansand
Akershus universitetssykehus HF
Oslo universitetssykehus HF, Ullevål, Kreftsenteret
Oncosalud Sac; Oncología
Instituto Nacional de Enfermedades Neoplasicas
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz
IPO do Porto; Servico de Oncologia Medica
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala
Centrul de Oncologie Sfantul Nectarie
Institutul Regional de Oncologie Iasi; Clinica de Hematologie
Oncocenter Timisoara
Hospital Sant Joan Despi- Moises Broggi; Servicio de Oncologia
Complejo Hospitalario de Navarra; Servicio de Oncologia
Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología
Hospital Clínic i Provincial; Servicio de Oncología
Institut Catala d Oncologia Hospital Duran i Reynals
Hospital Ramon y Cajal; Servicio de Oncologia
Hospital Universitario 12 de Octubre; Servicio de Oncologia
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
Hospital Universitario Virgen Macarena; Servicio de Oncologia
Hospital Universitari i Politecnic La Fe; Oncologia
Hospital Universitario Miguel Servet; Servicio Oncologia
Universitaetsspital Basel; Onkologie
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
Ramathibodi Hospital; Medicine/Oncology; Clinical Research Center
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
Ankara University Medical Faculty; Medikal Onkoloji
Ankara Oncology Hospital; Oncology
Akdeniz University Medical Faculty; Medical Oncology Department
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty; Medikal Onkoloji Departmani
?zmir Medical Point; Oncology
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
Royal United Hospital; Oncology Department
Velindre Cancer Centre
Western General Hospital; Edinburgh Cancer Center
Beatson West of Scotland Cancer Centre
University College London Hospitals NHS Foundation Trust - University College Hospital
Hammersmith Hospital; Garry Weston Centre
Christie Hospital NHS Trust
Freeman Hospital
Southampton General Hospital
Torbay Hospital; Oncology Department

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Molecularly-Guided Therapy

Platinum-Based Chemotherapy

Arm Description

Participants will be assigned to molecularly-guided therapy based on genomic profile.

Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).

Outcomes

Primary Outcome Measures

Progression Free Survival (PFS1)

Secondary Outcome Measures

Overall Survival (OS)

Objective Response Rate (ORR1)

Duration of Response (DOR1)

Disease Control Rate (DCR1)

Percentage of Participants with Adverse Events (AEs)

Full Information

NCT ID

NCT03498521

First Posted

April 5, 2018

Last Updated

August 24, 2023

Sponsor

Hoffmann-La Roche

Collaborators

Foundation Medicine, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT03498521

Brief Title

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Acronym

CUPISCO

Official Title

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Study Type

Interventional

2. Study Status

Record Verification Date

August 2023

Overall Recruitment Status

Active, not recruiting

Study Start Date

July 10, 2018 (Actual)

Primary Completion Date

February 14, 2023 (Actual)

Study Completion Date

June 9, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Hoffmann-La Roche

Collaborators

Foundation Medicine, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Product Manufactured in and Exported from the U.S.

Yes

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Cancer of Unknown Primary Site

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

790 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Molecularly-Guided Therapy

Arm Type

Experimental

Arm Description

Participants will be assigned to molecularly-guided therapy based on genomic profile.

Arm Title

Platinum-Based Chemotherapy

Arm Type

Active Comparator

Arm Description

Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).

Intervention Type

Drug

Intervention Name(s)

Alectinib

Intervention Description

Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention Type

Drug

Intervention Name(s)

Vismodegib

Intervention Description

Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention Type

Drug

Intervention Name(s)

Ipatasertib

Intervention Description

Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention Type

Drug

Intervention Name(s)

Olaparib

Intervention Description

Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention Type

Drug

Intervention Name(s)

Erlotinib

Intervention Description

Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention Type

Drug

Intervention Name(s)

Bevacizumab

Intervention Description

Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention Type

Drug

Intervention Name(s)

Vemurafenib

Intervention Description

Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention Type

Drug

Intervention Name(s)

Cobimetinib

Intervention Description

Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention Type

Drug

Intervention Name(s)

Trastuzumab Subcutaneous (SC)

Intervention Description

Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention Type

Drug

Intervention Name(s)

Pertuzumab

Intervention Description

Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)

Intervention Type

Drug

Intervention Name(s)

Atezolizumab

Intervention Description

Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention Type

Drug

Intervention Name(s)

Carboplatin

Intervention Description

Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.

Intervention Type

Drug

Intervention Name(s)

Paclitaxel

Intervention Description

Paclitaxel will be administered intravenously, 175 mg/m^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC

Intervention Type

Drug

Intervention Name(s)

Cisplatin

Intervention Description

Cisplatin will be administered intravenously, 60-75 mg/m^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.

Intervention Type

Drug

Intervention Name(s)

Gemcitabine

Intervention Description

Gemcitabine will be administered intravenously, 1000 mg/m^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.

Intervention Type

Drug

Intervention Name(s)

Entrectinib

Intervention Description

Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).

Intervention Type

Drug

Intervention Name(s)

Ivosidenib

Intervention Description

Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.

Intervention Type

Drug

Intervention Name(s)

Pemigatinib

Intervention Description

Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.

Primary Outcome Measure Information:

Title

Progression Free Survival (PFS1)

Time Frame

From randomization to the first occurrence of disease progression as assessed by the investigator according to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) or death from any cause, through the end of study (approximately 70 months)

Secondary Outcome Measure Information:

Title

Overall Survival (OS)

Time Frame

From randomization to death from any cause, through the end of study (approximately 70 months)

Title

Objective Response Rate (ORR1)

Time Frame

Two consecutive occurrences of complete or partial response >/=4 weeks apart

Title

Duration of Response (DOR1)

Time Frame

From the first documentation of a complete response (CR) or partial response (PR) to disease progression or death from any cause, whichever occurs first (up to approximately 70 months)

Title

Disease Control Rate (DCR1)

Time Frame

From randomization to death from any cause, through the end of study (approximately 70 months)

Title

Percentage of Participants with Adverse Events (AEs)

Time Frame

From baseline through the end of study (approximately 70 months)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Histologically-confirmed unresectable cancer of unknown primary site (CUP) diagnosed according to criteria defined in the 2015 European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for CUP No prior lines of systemic therapy for the treatment of CUP Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Candidate for platinum-based chemotherapy (according to the reference information for the intended chemotherapy) At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue sample </= 4 months old that is expected to be sufficient for generation of a comprehensive genomic profile at a central reference pathology laboratory Exclusion Criteria: Squamous cell CUP Participants who can be assigned to a specific subset of CUP for which a specific treatment is recommended by the 2015 ESMO Clinical Practice Guidelines for CUP or with a clinical and IHC profile indicative of a specific primary tumor (favorable prognosis CUP subsets): Poorly differentiated carcinoma with midline distribution; women with papillary adenocarcinoma of the peritoneal cavity; women with adenocarcinoma involving only the axillary lymph nodes; squamous cell carcinoma of the cervical lymph nodes; poorly differentiated neuroendocrine tumors; men with blastic bone metastases and elevated prostate-specific antigen (PSA); participants with a single, small, potentially resectable tumor; colon cancer-type CUP, including participants with a CK7 negative, CK20 positive, CDX-2 positive immunohistochemistry profile; CK7-positive, CK20-negative and TTF-1 positive tumors in a context suggestive of lung adenocarcinoma or thyroid cancer; IHC profile definitely indicative of breast cancer OR an IHC profile indicative of breast cancer and either a history of breast cancer or lymph nodes in the drainage areas of the breast; high-grade serious carcinoma histology and elevated CA125 tumor marker and/or a mass in the gynecological tract or any tumor mass or lymph node in the abdominal cavity; IHC profile suggestive of renal cell carcinoma and renal lesions, with a Bosniak classification higher than IIF; IHC profile compatible with cholangiocarcinoma or pancreatobiliary (or upper gastrointestinal carcinoma) AND 1 or 2 liver lesions without extrahepatic disease or with only pulmonary metastases and/or lymph nodes in the drainage areas of the liver Known presence of brain or spinal cord metastasis (including metastases that have been irradiated only) Histology and immunohistology profiles (per 2015 ESMO guidelines) that are not adenocarcinoma or poorly differentiated carcinoma/adenocarcinoma History or known presence of leptomeningeal disease Known human immunodeficiency virus (HIV) infection Significant cardiovascular disease Prior allogeneic stem cell or solid organ transplantation Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or for up to 7 months after the final dose of treatment

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Clinical Trials

Organizational Affiliation

Hoffmann-La Roche

Official's Role

Study Director

Facility Information:

Facility Name

Blacktown Hospital

City

Blacktown

State/Province

New South Wales

ZIP/Postal Code

2148

Country

Australia

Facility Name

Northern Cancer Institute

City

St Leonards

State/Province

New South Wales

ZIP/Postal Code

2065

Country

Australia

Facility Name

Icon Cancer Foundation

City

South Brisbane

State/Province

Queensland

ZIP/Postal Code

4101

Country

Australia

Facility Name

Flinders Medical Centre

City

Bedford Park

State/Province

South Australia

ZIP/Postal Code

5042

Country

Australia

Facility Name

Peter MacCallum Cancer Center

City

North Melbourne

State/Province

Victoria

ZIP/Postal Code

3051

Country

Australia

Facility Name

LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie

City

Graz

ZIP/Postal Code

8036

Country

Austria

Facility Name

Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

City

Salzburg

ZIP/Postal Code

5020

Country

Austria

Facility Name

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Chemotherapie & Infektionskrankhei

City

Wien

ZIP/Postal Code

1090

Country

Austria

Facility Name

Hospital Sao Rafael - HSR

City

Salvador

State/Province

ZIP/Postal Code

41253-190

Country

Brazil

Facility Name

Instituto Nacional de Cancer - INCa; Oncologia

City

Rio de Janeiro

State/Province

ZIP/Postal Code

20560-120

Country

Brazil

Facility Name

Hospital Nossa Senhora da Conceicao

City

Porto Alegre

State/Province

ZIP/Postal Code

91350-200

Country

Brazil

Facility Name

Hospital de Cancer de Barretos

City

Barretos

State/Province

ZIP/Postal Code

14784-400

Country

Brazil

Facility Name

Instituto do Cancer do Estado de Sao Paulo - ICESP

City

Sao Paulo

State/Province

ZIP/Postal Code

01246-000

Country

Brazil

Facility Name

MHAT Nadezhda

City

Sofia

ZIP/Postal Code

1330

Country

Bulgaria

Facility Name

MBAL Serdika EOOD

City

Sofia

ZIP/Postal Code

1632

Country

Bulgaria

Facility Name

Bradford Hill Centro de Investigaciones Clinicas

City

Recoleta

ZIP/Postal Code

8420383

Country

Chile

Facility Name

James Lind Centro de Investigación Del Cáncer

City

Temuco

ZIP/Postal Code

4800827

Country

Chile

Facility Name

Clinica del Country

City

Bogota

ZIP/Postal Code

11001

Country

Colombia

Facility Name

Inst. Nacional de Cancerologia; Clinica de Seno

City

Bogota

ZIP/Postal Code

111511

Country

Colombia

Facility Name

Oncomedica S.A.

City

Monteria

ZIP/Postal Code

230002

Country

Colombia

Facility Name

Clinical Hospital Centre Zagreb

City

Zagreb

ZIP/Postal Code

10000

Country

Croatia

Facility Name

Masarykuv onkologicky ustav

City

Brno

ZIP/Postal Code

656 53

Country

Czechia

Facility Name

Fakultni nemocnice Olomouc; Onkologicka klinika

City

Olomouc

ZIP/Postal Code

779 00

Country

Czechia

Facility Name

Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika

City

Praha 2

ZIP/Postal Code

128 08

Country

Czechia

Facility Name

Aarhus Universitetshospital; Afdeling for Eksperimentel Klinisk Onkologi

City

Aarhus N

ZIP/Postal Code

8200

Country

Denmark

Facility Name

Rigshospitalet; Onkologisk Klinik

City

København Ø

ZIP/Postal Code

2100

Country

Denmark

Facility Name

North Estonia Medical Centre, Oncology and hematology Clinic; Department of Chemotherapy

City

Tallinn

ZIP/Postal Code

13419

Country

Estonia

Facility Name

Helsinki University Central Hospital; Dept of Oncology

City

Helsinki

ZIP/Postal Code

00250

Country

Finland

Facility Name

Tampere University Hospital; Dept of Oncology

City

Tampere

ZIP/Postal Code

33520

Country

Finland

Facility Name

Ico - Paul Papin

City

Angers

ZIP/Postal Code

49000

Country

France

Facility Name

CHRU Besançon

City

Besançon

ZIP/Postal Code

25030

Country

France

Facility Name

Institut Bergonie; Oncologie

City

Bordeaux

ZIP/Postal Code

33076

Country

France

Facility Name

CRLCC-Francois Baclesse; Oncologie Médicale

City

Caen

ZIP/Postal Code

14076

Country

France

Facility Name

Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne

City

Clermont-ferrand

ZIP/Postal Code

63003

Country

France

Facility Name

Centre Leon Berard

City

Lyon

ZIP/Postal Code

69008

Country

France

Facility Name

Institut Paoli-Calmettes; Oncologie Medicale 1

City

Marseille Cedex 09

ZIP/Postal Code

13273

Country

France

Facility Name

Institut régional du Cancer Montpellier

City

Montpellier

ZIP/Postal Code

34298

Country

France

Facility Name

Centre Antoine Lacassagne

City

Nice

ZIP/Postal Code

06189

Country

France

Facility Name

Institut Curie; Oncologie Medicale

City

Paris

ZIP/Postal Code

75231

Country

France

Facility Name

CHU Lyon - Centre Hospitalier Lyon Sud

City

Pierre-Benite (Lyon)

ZIP/Postal Code

69495

Country

France

Facility Name

Centre Eugene Marquis; Service d'oncologie

City

Rennes

ZIP/Postal Code

35042

Country

France

Facility Name

CHU Strasbourg Hôpital Hautepierre

City

Strasbourg

ZIP/Postal Code

67098

Country

France

Facility Name

Hopital Foch; Oncologie

City

Suresnes

ZIP/Postal Code

92151

Country

France

Facility Name

Institut Gustave Roussy

City

Villejuif

ZIP/Postal Code

94805

Country

France

Facility Name

Universitätsklinikum Augsburg; II. Med. Klinik

City

Augsburg

ZIP/Postal Code

86156

Country

Germany

Facility Name

Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.

City

Berlin

ZIP/Postal Code

10117

Country

Germany

Facility Name

Onkologisches Zentrum - Onkologie Dachau

City

Dachau

ZIP/Postal Code

85221

Country

Germany

Facility Name

Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden

City

Dresden

ZIP/Postal Code

01307

Country

Germany

Facility Name

Universitätsklinikum Düsseldorf; Klinik für Hämatologie, Onkologie und Klinische Immunologie

City

Düsseldorf

ZIP/Postal Code

40225

Country

Germany

Facility Name

Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie

City

Essen

ZIP/Postal Code

45136

Country

Germany

Facility Name

Universitätsklinikum Frankfurt, UCT; Universitäres Centrum für Tumorerkrankungen

City

Frankfurt

ZIP/Postal Code

60590

Country

Germany

Facility Name

Universitätsklinikum Heidelberg;Innere Medizin V, Hämatologie/Onkologie

City

Heidelberg

ZIP/Postal Code

69120

Country

Germany

Facility Name

SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.

City

Heilbronn

ZIP/Postal Code

74078

Country

Germany

Facility Name

Universitätsklinikum Jena, Klinik für Innere Medizin II; Hämatologie und Internistische Onkologie

City

Jena

ZIP/Postal Code

07747

Country

Germany

Facility Name

Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik

City

Mainz

ZIP/Postal Code

55131

Country

Germany

Facility Name

Klinikum Mannheim III. Medizinische Klinik

City

Mannheim

ZIP/Postal Code

68167

Country

Germany

Facility Name

Klinikum der LMU München, Campus Großhadern, Krebszentrum München; Comprehensive Cancer Center LMU

City

München

ZIP/Postal Code

81377

Country

Germany

Facility Name

Universitätsklinikum Münster, Medizinische Klinik A, Translationale Onkologie

City

Münster

ZIP/Postal Code

48149

Country

Germany

Facility Name

RED-Oncology GmbH; Dres.Gerdt Hübner/Clemens Engels (Oldenburg)/Yael Bonnin-Gruber (Eutin)

City

Oldenburg / Holstein

ZIP/Postal Code

23758

Country

Germany

Facility Name

Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine

City

Athens

ZIP/Postal Code

115 22

Country

Greece

Facility Name

IASO General Hospital of Athens

City

Athens

ZIP/Postal Code

155 62

Country

Greece

Facility Name

Univ General Hosp Heraklion; Medical Oncology

City

Heraklion

ZIP/Postal Code

711 10

Country

Greece

Facility Name

Uni Hospital of Ioannina; Oncology Dept.

City

Ioannina

ZIP/Postal Code

455 00

Country

Greece

Facility Name

Theagenio Anticancer Hospital; 3Rd Oncology Clinic

City

Thessaloniki

ZIP/Postal Code

546 39

Country

Greece

Facility Name

Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly

City

Budapest

ZIP/Postal Code

1122

Country

Hungary

Facility Name

Budapesti Uzsoki Utcai Kórház; Onkoradiológiai Osztály

City

Budapest

ZIP/Postal Code

1145

Country

Hungary

Facility Name

Bács-Kiskun Vármegyei Oktatókórház; Onkoradiológiai Központ

City

Kecskemét

ZIP/Postal Code

6000

Country

Hungary

Facility Name

St Vincent'S Uni Hospital; Medical Oncology

City

Dublin

ZIP/Postal Code

D04 T6F4

Country

Ireland

Facility Name

Waterford Regional Hospital; Department Of Medical Oncology

City

Waterford

ZIP/Postal Code

X91 ER8E

Country

Ireland

Facility Name

Rabin MC; Davidof Center - Oncology Institute

City

Petach Tikva

ZIP/Postal Code

4941492

Country

Israel

Facility Name

Chaim Sheba medical center, Oncology division

City

Ramat Gan

ZIP/Postal Code

5262000

Country

Israel

Facility Name

Tel Aviv Sourasky Medical Ctr; Oncology

City

Tel Aviv

ZIP/Postal Code

6423906

Country

Israel

Facility Name

U. O. Oncologia Medica, Ospedale Santa Chiara

City

Pisa

State/Province

Basilicata

ZIP/Postal Code

56100

Country

Italy

Facility Name

Policlinico Univ. - A.O. Mater Domini; U.O. Di Oncoematologia

City

Catanzaro

State/Province

Calabria

ZIP/Postal Code

88100

Country

Italy

Facility Name

Istituto Nazionale Tumori Fondazione G. Pascale

City

Napoli

State/Province

Campania

ZIP/Postal Code

80131

Country

Italy

Facility Name

Arcispedale Santa Maria Nuova; Oncologia

City

Reggio Emilia

State/Province

Emilia-Romagna

ZIP/Postal Code

42100

Country

Italy

Facility Name

Asst Papa Giovanni XXIII; Oncologia Medica

City

Bergamo

State/Province

Lombardia

ZIP/Postal Code

24127

Country

Italy

Facility Name

Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck

City

Milano

State/Province

Lombardia

ZIP/Postal Code

20162

Country

Italy

Facility Name

IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima

City

Padova

State/Province

Veneto

ZIP/Postal Code

35128

Country

Italy

Facility Name

Aichi Cancer Center

City

Aichi

ZIP/Postal Code

464-8681

Country

Japan

Facility Name

National Cancer Center Hospital East

City

Chiba

ZIP/Postal Code

277-8577

Country

Japan

Facility Name

National Hospital Organization Kyushu Cancer Center

City

Fukuoka

ZIP/Postal Code

811-1395

Country

Japan

Facility Name

Seoul National University Hospital

City

Seoul

ZIP/Postal Code

03080

Country

Korea, Republic of

Facility Name

Asan Medical Center

City

Seoul

ZIP/Postal Code

05505

Country

Korea, Republic of

Facility Name

Samsung Medical Center

City

Seoul

ZIP/Postal Code

06351

Country

Korea, Republic of

Facility Name

Severance Hospital, Yonsei University Health System; Oncology

City

Seoul

ZIP/Postal Code

120-752

Country

Korea, Republic of

Facility Name

Riga East Clinical University Hospital Latvian Oncology Centre

City

Riga

ZIP/Postal Code

LV-1079

Country

Latvia

Facility Name

Health Pharma Professional Research

City

Cdmx

State/Province

Mexico CITY (federal District)

ZIP/Postal Code

03100

Country

Mexico

Facility Name

AVIX Investigación Clínica S.C

City

Monterrey

State/Province

Nuevo LEON

ZIP/Postal Code

64710

Country

Mexico

Facility Name

Erasmus MC

City

Rotterdam

ZIP/Postal Code

3015 GD

Country

Netherlands

Facility Name

Universitair Medisch Centrum Utrecht

City

Utrecht

ZIP/Postal Code

3584 CX

Country

Netherlands

Facility Name

Ziekenhuis VieCuri Medisch Centrum

City

Venlo

ZIP/Postal Code

5912 BL

Country

Netherlands

Facility Name

Sørlandet Sykehus Kristiansand

City

Kristiansand

ZIP/Postal Code

4604

Country

Norway

Facility Name

Akershus universitetssykehus HF

City

Lørenskog

ZIP/Postal Code

1478

Country

Norway

Facility Name

Oslo universitetssykehus HF, Ullevål, Kreftsenteret

City

Oslo

ZIP/Postal Code

0450

Country

Norway

Facility Name

Oncosalud Sac; Oncología

City

Lima

ZIP/Postal Code

Country

Peru

Facility Name

Instituto Nacional de Enfermedades Neoplasicas

City

Lima

ZIP/Postal Code

Lima 34

Country

Peru

Facility Name

Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii

City

Kraków

ZIP/Postal Code

30-688

Country

Poland

Facility Name

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz

City

Warszawa

ZIP/Postal Code

02-781

Country

Poland

Facility Name

IPO do Porto; Servico de Oncologia Medica

City

Porto

ZIP/Postal Code

4200-072

Country

Portugal

Facility Name

Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala

City

Cluj Napoca

ZIP/Postal Code

400015

Country

Romania

Facility Name

Centrul de Oncologie Sfantul Nectarie

City

Craiova

ZIP/Postal Code

200347

Country

Romania

Facility Name

Institutul Regional de Oncologie Iasi; Clinica de Hematologie

City

Iasi

ZIP/Postal Code

700483

Country

Romania

Facility Name

Oncocenter Timisoara

City

Timi?oara

ZIP/Postal Code

300166

Country

Romania

Facility Name

Hospital Sant Joan Despi- Moises Broggi; Servicio de Oncologia

City

Sant Joan Despí

State/Province

Barcelona

ZIP/Postal Code

08970

Country

Spain

Facility Name

Complejo Hospitalario de Navarra; Servicio de Oncologia

City

Pamplona

State/Province

Navarra

ZIP/Postal Code

31008

Country

Spain

Facility Name

Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro; Servicio de Oncología

City

Vigo

State/Province

Pontevedra

ZIP/Postal Code

36312

Country

Spain

Facility Name

Hospital Clínic i Provincial; Servicio de Oncología

City

Barcelona

ZIP/Postal Code

08036

Country

Spain

Facility Name

Institut Catala d Oncologia Hospital Duran i Reynals

City

Barcelona

ZIP/Postal Code

08908

Country

Spain

Facility Name

Hospital Ramon y Cajal; Servicio de Oncologia

City

Madrid

ZIP/Postal Code

28034

Country

Spain

Facility Name

Hospital Universitario 12 de Octubre; Servicio de Oncologia

City

Madrid

ZIP/Postal Code

28041

Country

Spain

Facility Name

Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia

City

Malaga

ZIP/Postal Code

29010

Country

Spain

Facility Name

Hospital Universitario Virgen Macarena; Servicio de Oncologia

City

Sevilla

ZIP/Postal Code

41009

Country

Spain

Facility Name

Hospital Universitari i Politecnic La Fe; Oncologia

City

Valencia

ZIP/Postal Code

46026

Country

Spain

Facility Name

Hospital Universitario Miguel Servet; Servicio Oncologia

City

Zaragoza

ZIP/Postal Code

50009

Country

Spain

Facility Name

Universitaetsspital Basel; Onkologie

City

Basel

ZIP/Postal Code

4031

Country

Switzerland

Facility Name

UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie

City

Zürich

ZIP/Postal Code

8091

Country

Switzerland

Facility Name

Ramathibodi Hospital; Medicine/Oncology; Clinical Research Center

City

Bangkok

ZIP/Postal Code

10400

Country

Thailand

Facility Name

Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology

City

Bangkok

ZIP/Postal Code

10700

Country

Thailand

Facility Name

Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology

City

Adana

ZIP/Postal Code

01230

Country

Turkey

Facility Name

Ankara University Medical Faculty; Medikal Onkoloji

City

Ankara

ZIP/Postal Code

06100

Country

Turkey

Facility Name

Ankara Oncology Hospital; Oncology

City

Ankara

ZIP/Postal Code

06200

Country

Turkey

Facility Name

Akdeniz University Medical Faculty; Medical Oncology Department

City

Antalya

ZIP/Postal Code

07070

Country

Turkey

Facility Name

Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

City

Edirne

ZIP/Postal Code

22030

Country

Turkey

Facility Name

Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty; Medikal Onkoloji Departmani

City

Istanbul

ZIP/Postal Code

34098

Country

Turkey

Facility Name

?zmir Medical Point; Oncology

City

Kar?iyaka

ZIP/Postal Code

35575

Country

Turkey

Facility Name

Hacettepe Uni Medical Faculty Hospital; Oncology Dept

City

Sihhiye/Ankara

ZIP/Postal Code

06230

Country

Turkey

Facility Name

Royal United Hospital; Oncology Department

City

Bath

ZIP/Postal Code

BA1 3NG

Country

United Kingdom

Facility Name

Velindre Cancer Centre

City

Cardiff

ZIP/Postal Code

CF14 2TL

Country

United Kingdom

Facility Name

Western General Hospital; Edinburgh Cancer Center

City

Edinburgh

ZIP/Postal Code

EH4 2XU

Country

United Kingdom

Facility Name

Beatson West of Scotland Cancer Centre

City

Glasgow

ZIP/Postal Code

G12 0YN

Country

United Kingdom

Facility Name

University College London Hospitals NHS Foundation Trust - University College Hospital

City

London

ZIP/Postal Code

NW1 2PG

Country

United Kingdom

Facility Name

Hammersmith Hospital; Garry Weston Centre

City

London

ZIP/Postal Code

W12 0HS

Country

United Kingdom

Facility Name

Christie Hospital NHS Trust

City

Manchester

ZIP/Postal Code

M20 4BX

Country

United Kingdom

Facility Name

Freeman Hospital

City

Newcastle upon Tyne

ZIP/Postal Code

NE7 7DN

Country

United Kingdom

Facility Name

Southampton General Hospital

City

Southampton

ZIP/Postal Code

SO16 6YD

Country

United Kingdom

Facility Name

Torbay Hospital; Oncology Department

City

Torquay

ZIP/Postal Code

TQ27AA

Country

United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

We'll reach out to this number within 24 hrs